|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Jean-Christophe Tellier||CEO & Executive Director||3,66M||N/A||1959|
|Ms. Sandrine Dufour CFA||Executive VP & CFO & Chief Corporate Development||N/A||N/A||1966|
|Dr. Kirsten Lund-Jurgensen Ph.D.||Executive Vice President of Supply & Technology Solutions||N/A||N/A||1960|
|Dr. Dhavalkumar D. Patel M.D., Ph.D.||Executive VP & Chief Scientific Officer||N/A||N/A||1961|
|Mr. Jean-Luc Fleurial||Executive VP & Chief Human Resources Officer||N/A||N/A||1965|
|Prof. Iris Low-Friedrich||Executive VP, Chief Medical Officer and Head of Development & Medical Patient Value Practices||N/A||N/A||1960|
|Mr. Emmanuel Caeymaex||Executive VP of Immunology Solutions & Head of US||N/A||N/A||1969|
|Ms. Caroline Vancoillie||Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions||N/A||N/A||N/A|
|Antje Witte||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Denelle J. Waynick Johnson J.D.||Executive VP & General Counsel||N/A||N/A||N/A|
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
El ISS Governance QualityScore de UCB SA, a día 28 de noviembre de 2023, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 1; Compensación: 4.